Behzad Rahimi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Behzad Rahimi has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Reza Hajizadeh
Department of Cardiology, Urmia University of Medical Sciences, Urmia, Iran
3 shared publications Asma Zamanian
Urmia Univ Med Sci, Dept Nutr, Sch Med, Orumiyeh, West Azerbaijan, Iran
2 shared publicationsAli Soleimany
Department of Cardiology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
1 shared publication- Alireza Rostamzadeh
Urmia Univ Med Sci, Dept Cardiol, Orumiyeh, Iran
1 shared publication Bahman Naghipour
Department of Anesthesiology, Madani Hospital, Tabriz University of Medical Sciences, Tabriz, IR Iran
1 shared publication- Behnam Askari
Department of Cardiovascular Surgery, Seyyed-al-Shohada Heart Center, Urmia University of Medical Sciences, Urmia, Iran
1 shared publication
Latest Publications
- Open Access
- 1 April 2025
- Published by Apex Publishing in Health Science Monitor
- Vol. 4 (2) , 92-102
Gender-related differences in manifestations, complications, and mortality rate of systolic heart failure patients
Background & Aims: Cardiovascular diseases (CVD) are one of the leading causes of death worldwide. Important differences in comorbidities and clinical characteristics exist between women and men with heart failure. This study aimed to explore the influence of gender on the clinical manifestations, complications, and mortality of patients with systolic ...
- 1 April 2025
- Published by Apex Publishing in Health Science Monitor
- Vol. 4 (2) , 92-102
Open AccessGender-related differences in manifestations, complications, and mortality rate of systolic heart failure patients
Background & Aims: Cardiovascular diseases (CVD) are one of the leading causes of death worldwide. Important differences in comorbidities and clinical characteristics exist between women and men with heart failure. This study aimed to explore the influence of gender on the clinical manifestations, complications, and mortality of patients with systolic ...
- Open Access
- 26 March 2024
- Published by Damar Cerrahi Dergisi - Turkish Journal of Vascular Surgery in Turkish Journal of Vascular Surgery
- Vol. 33 (1) , 26-32
Factors associated with in-hospital mortality and morbidity of patients with dissection of aorta type A, undergoing repair surgery
Aim: Acute aortic dissection type A (AADA) is a life-threatening emergency with high mortality rates. Surgical intervention is the preferred and potentially life-saving treatment, but perioperative mortality remains a significant concern. Identifying the risk factors associated with surgical mortality, morbidity, and survival rates is essential. Therefore, this study aimed to characterize the preoperative and intraoperative risk factors for death during surgical repair of AADA.Material and Methods: We included 64 consecutive patients who underwent surgical repair between April 2013 and March 2021 in a tertiary heart center. Perioperative characteristics and variables were collected and analyzed to find any correlation between them and in-hospital Outcomes.Results: Aortic dissection surgery was performed on an average of 8 patients annually, accounting for approximately 1.7% (64/3757) of all open-heart surgery cases. The in-hospital mortality rate was 28% (18/64). The main predisposing factors for in-hospital death were cardiac failure (11.1%), stroke (16.7%), uncontrollable hemorrhage (27.8%), renal failure (11.1%), respiratory failure (11.1%), and postoperative multi-organ failure (22.2%). We found no associations between cardiopulmonary bypass duration and mortality. During the routine use of cerebral protective perfusion, we did not encounter any cases of coma. Left ventricular hypertrophy, a short distance of intimal tear to the aortic valve, and renal failure were associated with postoperative bleeding tendency.Conclusion: Our study showed that multiple factors such as heart failure, uncontrolled bleeding, and respiratory failure increase in-hospital mortality of patients with dissection of aorta type A, but duration of surgery does not have any association with in-hospital death.
- 26 March 2024
- Published by Damar Cerrahi Dergisi - Turkish Journal of Vascular Surgery in Turkish Journal of Vascular Surgery
- Vol. 33 (1) , 26-32
Open AccessFactors associated with in-hospital mortality and morbidity of patients with dissection of aorta type A, undergoing repair surgery
Aim: Acute aortic dissection type A (AADA) is a life-threatening emergency with high mortality rates. Surgical intervention is the preferred and potentially life-saving treatment, but perioperative mortality remains a significant concern. Identifying the risk factors associated with surgical mortality, morbidity, and survival rates is essential. Therefore, this study aimed to characterize the preoperative and intraoperative risk factors for death during surgical repair of AADA.Material and Methods: We included 64 consecutive patients who underwent surgical repair between April 2013 and March 2021 in a tertiary heart center. Perioperative characteristics and variables were collected and analyzed to find any correlation between them and in-hospital Outcomes.Results: Aortic dissection surgery was performed on an average of 8 patients annually, accounting for approximately 1.7% (64/3757) of all open-heart surgery cases. The in-hospital mortality rate was 28% (18/64). The main predisposing factors for in-hospital death were cardiac failure (11.1%), stroke (16.7%), uncontrollable hemorrhage (27.8%), renal failure (11.1%), respiratory failure (11.1%), and postoperative multi-organ failure (22.2%). We found no associations between cardiopulmonary bypass duration and mortality. During the routine use of cerebral protective perfusion, we did not encounter any cases of coma. Left ventricular hypertrophy, a short distance of intimal tear to the aortic valve, and renal failure were associated with postoperative bleeding tendency.Conclusion: Our study showed that multiple factors such as heart failure, uncontrolled bleeding, and respiratory failure increase in-hospital mortality of patients with dissection of aorta type A, but duration of surgery does not have any association with in-hospital death.
- 1 November 2020
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 14 (11) , OC9-OC13
The Effect of Omega-3 Fatty Acids Supplementation on the Improvement of Metabolic Syndrome in Patients with Ischemic Heart Disease: A Double-blind, Randomised, Placebo-controlled Trial
Introduction: Metabolic syndrome is a set of metabolic abnormalities that increase the risk of cardiovascular disease. Omega-3 fatty acids may play a role in improving metabolic syndrome by affecting endothelial status. Aim: To study the effect of omega-3 fatty acids on metabolic syndrome in patients with cardiac ischemia. Materials and Methods: This was a 12-weeks, double-blind, randomised, placebo-controlled trial. Ninety patients with a history of cardiac ischemia and metabolic syndrome were randomly divided into intervention (n=45) and placebo (n=45) groups. In the end, 86 people completed the study. The intervention group consumed daily Omega-3 capsules containing 1000 mg fish oil, 180 mg EPA and 120 mg DHA. The placebo group took gelatin-containing capsules. Serum triglycerides, Fasting Blood Sugar (FBS), cholesterol, Low-Density Lipoprotein (LDL), High-Density Lipoprotein (HDL) were measured at baseline and the end of the study and weight, waist circumference, Body Mass Index (BMI) were measured at baseline, middle and end of the study. Independent t-test was used for comparing the baseline and mean changes. The variables that measured in three times were compared using repeated measurement test between two groups. Paired t-test was performed to compare within group differences. Results: Serum triglyceride, FBS, weight and systolic blood pressure decreased and serum HDL increased compared to the placebo group. There were no significant changes in serum cholesterol, LDL, BMI, waist circumference and diastolic blood pressure after omega-3 administration. Conclusion: Omega-3 supplementation for 12 weeks improves some of the indicators of metabolic syndrome in individuals with ischemic heart disease. (IRCT Code: IRCT20190819044563N1).
- 1 November 2020
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 14 (11) , OC9-OC13
The Effect of Omega-3 Fatty Acids Supplementation on the Improvement of Metabolic Syndrome in Patients with Ischemic Heart Disease: A Double-blind, Randomised, Placebo-controlled Trial
Introduction: Metabolic syndrome is a set of metabolic abnormalities that increase the risk of cardiovascular disease. Omega-3 fatty acids may play a role in improving metabolic syndrome by affecting endothelial status. Aim: To study the effect of omega-3 fatty acids on metabolic syndrome in patients with cardiac ischemia. Materials and Methods: This was a 12-weeks, double-blind, randomised, placebo-controlled trial. Ninety patients with a history of cardiac ischemia and metabolic syndrome were randomly divided into intervention (n=45) and placebo (n=45) groups. In the end, 86 people completed the study. The intervention group consumed daily Omega-3 capsules containing 1000 mg fish oil, 180 mg EPA and 120 mg DHA. The placebo group took gelatin-containing capsules. Serum triglycerides, Fasting Blood Sugar (FBS), cholesterol, Low-Density Lipoprotein (LDL), High-Density Lipoprotein (HDL) were measured at baseline and the end of the study and weight, waist circumference, Body Mass Index (BMI) were measured at baseline, middle and end of the study. Independent t-test was used for comparing the baseline and mean changes. The variables that measured in three times were compared using repeated measurement test between two groups. Paired t-test was performed to compare within group differences. Results: Serum triglyceride, FBS, weight and systolic blood pressure decreased and serum HDL increased compared to the placebo group. There were no significant changes in serum cholesterol, LDL, BMI, waist circumference and diastolic blood pressure after omega-3 administration. Conclusion: Omega-3 supplementation for 12 weeks improves some of the indicators of metabolic syndrome in individuals with ischemic heart disease. (IRCT Code: IRCT20190819044563N1).
- Open Access
- 28 July 2020
- Published by DoNotEdit in Iranian Red Crescent Medical Journal
- Vol. 22 (7)
The Role of Vitamin D Supplementation in the Treatment of Primary Hypertension: A Double-Blinded Randomized Placebo-Controlled Clinical Trial
Background: Hypertension is one of the most serious global concerns since it has affected over 1.2 billion people. Objectives: The present study aimed to determine the effect of vitamin D supplementation on blood pressure, fasting blood sugar, and lipid profile in hypertensive patients with vitamin D deficiency. Methods: In this double-blinded randomized placebo-controlled clinical trial study, 116 hypertensive patients (intervention and placebo groups, 58 each) with vitamin D deficiency (< 30 ng/mL with ECL) for 14 weeks, started from the beginning of autumn 2019 in Seyed-al-Shohada Educational Hospital in Urmia City. Fifty-five patients (49%) were male with the mean vitamin D 15.89 ± 5.09 ng/mL and 57 females with 17.29 ± 6.31 ng/mL. In a stratified blocked randomization scheme, the patients were randomly allocated into similar sized intervention and control groups based on body mass index (BMI), then the randomization with four block size was performed in each of strata by random allocation software. The intervention group received six doses of 50,000 IU vitamin D supplements for 6 weeks, then two supplements for two following months (one capsule per month). Blood pressure (24/h blood pressure measured by an ambulatory blood pressure monitoring device), vitamin D, FBS, and lipid profile (HDL, LDL, CL, and TG) were all measured at baseline and end of the study. Physical activity (measured by short IPAQ questionnaire), sun exposure using a questionnaire, dietary intake of vitamin D using three 24-hour recalls during the intervention, and anthropometric indices were measured at baseline, middle, and end of the study. Fifty-six patients in each group completed the study. The study was approved by the Ethics Committee of the Urmia University of Medical Sciences (ethics code: IR.UMSU.REC.1398.192). Results: The office blood pressure, 24-h systolic blood pressure (SBP) and diastolic blood pressure (DBP), nighttime SBP and DBP were significantly reduced in the intervention group compared to the control group, whereas the reduction of daytime SBP and DBP was not statistically significant. Vitamin D supplementation significantly decreased serum triglyceride, cholesterol, and LDL levels. Conclusions: Vitamin D supplementation had positive effects on blood pressure, triglyceride, cholesterol, and LDL levels in patients with low serum vitamin D. Keywords Vitamin D Hypertension Vitamin D Deficiency Ambulatory Blood Pressure Monitoring
- 28 July 2020
- Published by DoNotEdit in Iranian Red Crescent Medical Journal
- Vol. 22 (7)
Open AccessThe Role of Vitamin D Supplementation in the Treatment of Primary Hypertension: A Double-Blinded Randomized Placebo-Controlled Clinical Trial
Background: Hypertension is one of the most serious global concerns since it has affected over 1.2 billion people. Objectives: The present study aimed to determine the effect of vitamin D supplementation on blood pressure, fasting blood sugar, and lipid profile in hypertensive patients with vitamin D deficiency. Methods: In this double-blinded randomized placebo-controlled clinical trial study, 116 hypertensive patients (intervention and placebo groups, 58 each) with vitamin D deficiency (< 30 ng/mL with ECL) for 14 weeks, started from the beginning of autumn 2019 in Seyed-al-Shohada Educational Hospital in Urmia City. Fifty-five patients (49%) were male with the mean vitamin D 15.89 ± 5.09 ng/mL and 57 females with 17.29 ± 6.31 ng/mL. In a stratified blocked randomization scheme, the patients were randomly allocated into similar sized intervention and control groups based on body mass index (BMI), then the randomization with four block size was performed in each of strata by random allocation software. The intervention group received six doses of 50,000 IU vitamin D supplements for 6 weeks, then two supplements for two following months (one capsule per month). Blood pressure (24/h blood pressure measured by an ambulatory blood pressure monitoring device), vitamin D, FBS, and lipid profile (HDL, LDL, CL, and TG) were all measured at baseline and end of the study. Physical activity (measured by short IPAQ questionnaire), sun exposure using a questionnaire, dietary intake of vitamin D using three 24-hour recalls during the intervention, and anthropometric indices were measured at baseline, middle, and end of the study. Fifty-six patients in each group completed the study. The study was approved by the Ethics Committee of the Urmia University of Medical Sciences (ethics code: IR.UMSU.REC.1398.192). Results: The office blood pressure, 24-h systolic blood pressure (SBP) and diastolic blood pressure (DBP), nighttime SBP and DBP were significantly reduced in the intervention group compared to the control group, whereas the reduction of daytime SBP and DBP was not statistically significant. Vitamin D supplementation significantly decreased serum triglyceride, cholesterol, and LDL levels. Conclusions: Vitamin D supplementation had positive effects on blood pressure, triglyceride, cholesterol, and LDL levels in patients with low serum vitamin D. Keywords Vitamin D Hypertension Vitamin D Deficiency Ambulatory Blood Pressure Monitoring
- Open Access
- 1 February 2020
- Published by Maad Rayan Publishing Company in Journal of Research in Clinical Medicine
- Vol. 8 (1) , 40
Association of neutrophil count and neutrophil to lymphocyte ratio with coronary artery ectasia
Objective: CAE characterized as diffuse dilatation of epicardial coronary arteries has been shown to have association with risks of death and myocardial infarction. Neutrophil count and neutrophil to lymphocyte ratio (NLR) are cost effective, available and rapidly measureable inflammatory marker. In this study we decided to investigate the association between these factors as inflammatory markers and CAE severity. Methods: In this cross sectional study 577 patients who underwent coronary angiography between September 2016 and September 2017 were evaluated. According to angiography findings patients were divided into four groups: 1-normal coronary artery, 2-coronary artery diseased group, 3-low risk coronary artery ectasia (CAE) and 4-high risk CAE. Results: In CAE group 61 patients (52.1%) had one vessel involvement and defined as low risk and 56 patients (47.9%) had two or more vessel involvement and grouped as high risk CAE. NLR was non-significantly higher in CAD group following high risk CAE group. (2.61±0.51 and 2.33±0.11 respectively) absolute neutrophil count was significantly higher in CAD and high risk CAE groups. Conclusion: Neutrophil count is an inflammatory marker with good association with coronary artery ectasia and coronary artery disease.
- 1 February 2020
- Published by Maad Rayan Publishing Company in Journal of Research in Clinical Medicine
- Vol. 8 (1) , 40
Open AccessAssociation of neutrophil count and neutrophil to lymphocyte ratio with coronary artery ectasia
Objective: CAE characterized as diffuse dilatation of epicardial coronary arteries has been shown to have association with risks of death and myocardial infarction. Neutrophil count and neutrophil to lymphocyte ratio (NLR) are cost effective, available and rapidly measureable inflammatory marker. In this study we decided to investigate the association between these factors as inflammatory markers and CAE severity. Methods: In this cross sectional study 577 patients who underwent coronary angiography between September 2016 and September 2017 were evaluated. According to angiography findings patients were divided into four groups: 1-normal coronary artery, 2-coronary artery diseased group, 3-low risk coronary artery ectasia (CAE) and 4-high risk CAE. Results: In CAE group 61 patients (52.1%) had one vessel involvement and defined as low risk and 56 patients (47.9%) had two or more vessel involvement and grouped as high risk CAE. NLR was non-significantly higher in CAD group following high risk CAE group. (2.61±0.51 and 2.33±0.11 respectively) absolute neutrophil count was significantly higher in CAD and high risk CAE groups. Conclusion: Neutrophil count is an inflammatory marker with good association with coronary artery ectasia and coronary artery disease.
- Open Access
- 9 March 2016
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 5 (3) , e002919
Short‐Term High‐Dose Vitamin E to Prevent Contrast Medium–Induced Acute Kidney Injury in Patients With Chronic Kidney Disease Undergoing Elective Coronary Angiography: A Randomized Placebo‐Controlled Trial
Background: Contrast medium–induced acute kidney injury ( CIAKI ) is a leading cause of acquired renal impairment. The effects of antioxidants have been conflicting regarding the prevention of CIAKI . We performed a study of vitamin E use to decrease CIAKI in patients undergoing elective coronary angiography. Methods and Results: In a placebo‐controlled randomized trial at 2 centers in Iran, 300 patients with chronic kidney disease—defined as estimated glomerular filtration rate 2 —were randomized 1:1 to receive 0.9% saline infusion 12 hours prior to and after intervention combined with 600 mg vitamin E 12 hours before plus 400 mg vitamin E 2 hours before coronary angiography or to receive placebo. The primary end point was the development of CIAKI, defined as an increase ≥0.5 mg/dL or ≥25% in serum creatinine that peaked within 72 hours. Based on an intention‐to‐treat analysis, CIAKI developed in 10 (6.7%) and 21 (14.1%) patients in the vitamin E and placebo groups, respectively ( P =0.037). Change in white blood cell count from baseline to peak value was greater in the vitamin E group compared with the placebo group (−500 [−1500 to 200] versus 100 [−900 to 600]×10 3 /mL , P =0.001). In multivariate analysis, vitamin E (odds ratio 0.408, 95% CI 0.170–0.982, P =0.045) and baseline Mehran score (odds ratio 1.257, 95% CI 1.007–1.569; P =0.043) predicted CIAKI. Conclusions: Prophylactic short‐term high‐dose vitamin E combined with 0.9% saline infusion is superior to placebo for prevention of CIAKI in patients undergoing elective coronary angiography. Clinical Trial Registration: URL : https://www.clinicaltrials.gov/ . Unique identifier: NCT 02070679.
- 9 March 2016
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 5 (3) , e002919
Open AccessShort‐Term High‐Dose Vitamin E to Prevent Contrast Medium–Induced Acute Kidney Injury in Patients With Chronic Kidney Disease Undergoing Elective Coronary Angiography: A Randomized Placebo‐Controlled Trial
Background: Contrast medium–induced acute kidney injury ( CIAKI ) is a leading cause of acquired renal impairment. The effects of antioxidants have been conflicting regarding the prevention of CIAKI . We performed a study of vitamin E use to decrease CIAKI in patients undergoing elective coronary angiography. Methods and Results: In a placebo‐controlled randomized trial at 2 centers in Iran, 300 patients with chronic kidney disease—defined as estimated glomerular filtration rate 2 —were randomized 1:1 to receive 0.9% saline infusion 12 hours prior to and after intervention combined with 600 mg vitamin E 12 hours before plus 400 mg vitamin E 2 hours before coronary angiography or to receive placebo. The primary end point was the development of CIAKI, defined as an increase ≥0.5 mg/dL or ≥25% in serum creatinine that peaked within 72 hours. Based on an intention‐to‐treat analysis, CIAKI developed in 10 (6.7%) and 21 (14.1%) patients in the vitamin E and placebo groups, respectively ( P =0.037). Change in white blood cell count from baseline to peak value was greater in the vitamin E group compared with the placebo group (−500 [−1500 to 200] versus 100 [−900 to 600]×10 3 /mL , P =0.001). In multivariate analysis, vitamin E (odds ratio 0.408, 95% CI 0.170–0.982, P =0.045) and baseline Mehran score (odds ratio 1.257, 95% CI 1.007–1.569; P =0.043) predicted CIAKI. Conclusions: Prophylactic short‐term high‐dose vitamin E combined with 0.9% saline infusion is superior to placebo for prevention of CIAKI in patients undergoing elective coronary angiography. Clinical Trial Registration: URL : https://www.clinicaltrials.gov/ . Unique identifier: NCT 02070679.
- Open Access
- 1 December 2014
- Vol. 8 (4) , 161-165
QT Dispersion after Thrombolytic Therapy
QT dispersion (QTd) is equal to longer QTc minus shorter QTc measured by 12-lead electrocardiogram (ECG). QTd reflects inhomogeneity in repolarization of ventricular myocardium and because of easy and fast measurement of QTd, it can be used to predict high-risk patients for dysrhythmia after Acute Myocardial Infarction (AMI). This study aimed to assess the effect of thrombolytic therapy on QTd before and 1 hour and 4 days after beginning of thrombolytic therapy. The patients with chest pain and ST Elevated Myocardial Infarction (STEMI) that underwent thrombolytic therapy were enrolled into this study. Streptokinase was the thrombolytic agent in all the patients. Standard 12-lead (ECG) was evaluated before beginning of thrombolytic therapy (QTd 1) and 1 hour (QTd2) and 4 days (QTd3) after thrombolytic therapy. First, ECG was magnified × 10 for exact calculation of QT and QTd. After all, the variables were compared using one–way analysis of variance (ANOVA). Besides, P ≤ 0.05 was considered as statistically significant. This study was conducted on 160 patients. The results revealed no significant differences among QTd 1, QTd 2, and QTd 3 (P > 0.05). At inferior AMI, however, a significant difference was observed among QTd1, QTd2, and QTd3 (P = 0.031). Thrombolytic therapy had no significant effects on QTd. Thus, thrombolytic therapy does not increase the risk of arrhythmia.
- 1 December 2014
- Vol. 8 (4) , 161-165
Open AccessQT Dispersion after Thrombolytic Therapy
QT dispersion (QTd) is equal to longer QTc minus shorter QTc measured by 12-lead electrocardiogram (ECG). QTd reflects inhomogeneity in repolarization of ventricular myocardium and because of easy and fast measurement of QTd, it can be used to predict high-risk patients for dysrhythmia after Acute Myocardial Infarction (AMI). This study aimed to assess the effect of thrombolytic therapy on QTd before and 1 hour and 4 days after beginning of thrombolytic therapy. The patients with chest pain and ST Elevated Myocardial Infarction (STEMI) that underwent thrombolytic therapy were enrolled into this study. Streptokinase was the thrombolytic agent in all the patients. Standard 12-lead (ECG) was evaluated before beginning of thrombolytic therapy (QTd 1) and 1 hour (QTd2) and 4 days (QTd3) after thrombolytic therapy. First, ECG was magnified × 10 for exact calculation of QT and QTd. After all, the variables were compared using one–way analysis of variance (ANOVA). Besides, P ≤ 0.05 was considered as statistically significant. This study was conducted on 160 patients. The results revealed no significant differences among QTd 1, QTd 2, and QTd 3 (P > 0.05). At inferior AMI, however, a significant difference was observed among QTd1, QTd2, and QTd3 (P = 0.031). Thrombolytic therapy had no significant effects on QTd. Thus, thrombolytic therapy does not increase the risk of arrhythmia.
- 26 November 2014
- Vol. 63 (3) , 164-6
Serum CA-125 level in patients with chronic obstructive pulmonary disease with and without pulmonary hypertension.
Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disease and is going to be the 3rd most common cause of death worldwide. Pulmonary hypertension (PH) has severely bad influence on prognosis in COPD patients. Hence, early diagnosis of it is important for appropriate therapy. Echocardiography is used for this purpose, which requires cardiologist and expensive equipment which may not be available anywhere. CA-125, a biomarker of ovarian cancer, has shown to be associated with left ventricular failure. We aimed to show the relationship between CA-125 levels and PH in patients with COPD. Ninety patients with stable COPD were enrolled into the study. Levels of CA-725 were measured from venous blood, and in the same day systolic pulmonary artery pressure (sPAP) was measured by transthoracic echocardiography. Of 90 Patients 57 had PH and 39 had not. Patients with PH had significantly higher CA- 125 levels compared with controls (mean 39.15 U/ mL vs. 24.22 U/mL, P < 0.04). Levels of CA-125 were correlated with sPAP (r=017, P=0.01). The CA-125 biomarker can be used to identify COPD patients with pulmonary hypertension. Since it is cheap and easily available it can help in centers with less access to echocardiography.
- 26 November 2014
- Vol. 63 (3) , 164-6
Serum CA-125 level in patients with chronic obstructive pulmonary disease with and without pulmonary hypertension.
Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disease and is going to be the 3rd most common cause of death worldwide. Pulmonary hypertension (PH) has severely bad influence on prognosis in COPD patients. Hence, early diagnosis of it is important for appropriate therapy. Echocardiography is used for this purpose, which requires cardiologist and expensive equipment which may not be available anywhere. CA-125, a biomarker of ovarian cancer, has shown to be associated with left ventricular failure. We aimed to show the relationship between CA-125 levels and PH in patients with COPD. Ninety patients with stable COPD were enrolled into the study. Levels of CA-725 were measured from venous blood, and in the same day systolic pulmonary artery pressure (sPAP) was measured by transthoracic echocardiography. Of 90 Patients 57 had PH and 39 had not. Patients with PH had significantly higher CA- 125 levels compared with controls (mean 39.15 U/ mL vs. 24.22 U/mL, P < 0.04). Levels of CA-125 were correlated with sPAP (r=017, P=0.01). The CA-125 biomarker can be used to identify COPD patients with pulmonary hypertension. Since it is cheap and easily available it can help in centers with less access to echocardiography.